BeiGene (BGNE) Appoints Olivier Brandicourt to its Board

BeiGene, Ltd. (NASDAQ: BGNE), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board.

Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016.

“Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene’s Board of Directors to include deep expertise in leading multinational growth companies, spearheading launches in a range of therapeutic areas and scaling into new geographies,” said John V. Oyler, Chairman, CEO and Co-Founder at BeiGene. “The Board looks forward to working with Dr. Brandicourt, who drove excellence as an outstanding leader for multiple global pharmaceutical brands, as we continue our evolution as a next-generation oncology innovator. Tom has been an invaluable member of the board with service dating back before the Company’s IPO. We thank him for his dedicated service and incredible contributions to BeiGene’s global success and wish him well.”

“I am pleased to join BeiGene’s Board and help advance the Company’s mission to bring innovative cancer medicines to more patients around the world,” said Dr. Brandicourt. “Through my decades of pharmaceuticals and medical leadership, I have committed my career to ensuring equitable global access to improve patient outcomes. It is an honor to serve alongside my fellow Board members who share my commitment to this goal.”

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• JATT III Acquisition Corp closes $69M IPO on Nasdaq
• Pinterest CFO resigns, interim replacement named